The New York State Psychiatric Institute
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1895-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.nyspi.org
Clinical Trials
435
Active:7
Completed:309
Trial Phases
6 Phases
Early Phase 1:4
Phase 1:59
Phase 2:113
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (413 trials with phase data)• Click on a phase to view related trials
Not Applicable
143 (34.6%)Phase 2
113 (27.4%)Phase 4
76 (18.4%)Phase 1
59 (14.3%)Phase 3
18 (4.4%)Early Phase 1
4 (1.0%)Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts
Not Applicable
Not yet recruiting
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- Drug: Ketamine hydrochloride infusion
- First Posted Date
- 2025-08-24
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 12
- Registration Number
- NCT07139106
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Helping Adults With Obsessive-Compulsive Disorder Succeed at Work
Not Applicable
Not yet recruiting
- Conditions
- Obsessive-Compulsive Disorder (OCD)
- First Posted Date
- 2025-08-15
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 40
- Registration Number
- NCT07124780
A Multimodal Imaging Study of Dopamine in Early Psychosis
Phase 1
Not yet recruiting
- Conditions
- Clinical High Risk for Psychosis (CHR)
- Interventions
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 115
- Registration Number
- NCT06977308
Olfactory Training in Mild Cognitive Impairment
Not Applicable
Recruiting
- Conditions
- Mild Cognitive Impairment
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- Jeffrey Motter
- Target Recruit Count
- 30
- Registration Number
- NCT06825403
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Exercise and Olanzapine-samidorphan
Phase 4
Recruiting
- Conditions
- Schizophenia DisorderSchizoaffective DisorderBipolar Disorder I or IIBipolar Disorder NOS
- Interventions
- Drug: Olanzapine-samidorphan + exercise
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06740890
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 87
- Next
News
Psilocybin Shows Promise in Reducing Symptoms of Body Dysmorphic Disorder
A pilot study indicates that psilocybin significantly reduced symptoms in individuals with body dysmorphic disorder (BDD).